Addex Therapeutics Ltd (ADXN)
ADXN trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC filing XBRL, 20-F (ifrs-full:RevenueFromContractsWithCustomers), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1574232/000110465926062447/0001104659-26-062447-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLoss), fiscal year ended 2025-12-31. Converted from CHF at 0.8384 per USD (today's ECB or Federal Reserve reference rate).
Profile
| Field | Value |
|---|---|
| Ticker | ADXN on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Switzerland |
| IPO year | Not reported by the screener |
| SEC CIK | 0001574232 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | Switzerland |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $36K |
| Net income | -$8.0M |
| Operating income | -$3.4M |
| Net margin | -22448.4% |
| Operating margin | -9390.8% |
| Revenue growth | -92.6% |
| Cash | $2.0M |
| Total assets | $7.6M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 182.5× |
Reported in CHF; shown in US dollars.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These factors individually and collectively indicate that a material uncertainty exists that raises substantial doubt about the Group's ability to continue as a going concern for one year from the date of issuance of these consolidated financial statements." | 20-F 2026-05-15 |
| Cash and burn | 1.6M CHF cash; operating cash flow -543K CHF a quarter. | Report 2025-12-31 |
| Shares outstanding | No cover-page share count in XBRL | Cover page 2025-12-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2025-12-10 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | BDO AG, Zurich, Switzerland | PCAOB Form AP 2026-06-01 |
| Late filings, 12 months | 1 NT notice | NT 20-F 2026-04-30 |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | 30K CHF | -6.7M CHF | -2.2M CHF | 1.6M CHF | 0 CHF | 30K CHF | 20-F 2026-05-15 |
| FY 2024 2024-12-31 | 404K CHF | 7.1M CHF | -5.4M CHF | 3.3M CHF | 0 CHF | 404K CHF | 20-F 2025-05-15 |
| FY 2023 2023-12-31 | 1.6M CHF | -10.6M CHF | -8.0M CHF | 3.9M CHF | 0 CHF | 1.6M CHF | 20-F 2025-05-15 |
| FY 2022 2022-12-31 | 1.4M CHF | -20.8M CHF | -16.4M CHF | 7.0M CHF | 0 CHF | 1.4M CHF | 20-F 2025-05-15 |
| FY 2021 2021-12-31 | 2.9M CHF | -15.4M CHF | -14.7M CHF | 20.5M CHF | 0 CHF | 2.9M CHF | 20-F 2024-04-18 |
| FY 2020 2020-12-31 | 3.6M CHF | -12.9M CHF | -12.2M CHF | 18.7M CHF | 0 CHF | 3.6M CHF | 20-F 2023-03-30 |
| FY 2019 2019-12-31 | 2.8M CHF | -14.8M CHF | -9.5M CHF | 31.5M CHF | 0 CHF | 2.8M CHF | 20-F 2022-03-10 |
| FY 2018 2018-12-31 | 6.0M CHF | -1.6M CHF | 1.8M CHF | 31.5M CHF | 0 CHF | 6.0M CHF | 20-F 2021-03-11 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months). Amounts in CHF.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2025-12-10 |
| Latest annual report FORM 20-F | 20-F | 2026-05-15 |
| Latest quarterly / interim FORM 6-K | 6-K | 2026-11-12 |
Source: SEC EDGAR submissions feed, 289 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +40.0% |
| 1 month | +34.9% |
| 3 months | -31.8% |
| Year to date | -47.4% |
| 1 year | -52.8% |
| From 52-week high | -54.8% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ENVB | Enveric Biosciences Inc. | $1.44 | -4.95% | $6.4M |
| TOVX | Theriva Biologics Inc. | $0.1400 | -2.85% | $6.4M |
| TCRT | Alaunos Therapeutics Inc. | $1.60 | -1.84% | $6.7M |
| SNGX | Soligenix Inc. | $0.2882 | -10.22% | $6.7M |
| TPST | Tempest Therapeutics Inc. | $0.3418 | -10.50% | $6.8M |
| FBLG | FibroBiologics Inc. | $0.9034 | -2.00% | $6.1M |
| XCUR | Exicure Inc. | $1.07 | -0.93% | $7.0M |
| LGVN | Longeveron Inc. | $2.14 | -14.06% | $7.2M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier